Evaluation of minimal residual disease in relapsed/refractory multiple myeloma patients treated with venetoclax or placebo in combination with bortezomib and dexamethasone: BELLINI study analyses.

Autores de IIS La Fe

• 

  Javier De La Rubia Comos

  Autor

Participantes ajenos a IIS La Fe

• Moreau, P
• Harrison, SJ
• Cavo, M
• Popat, R
• Hungria, V
• Salwender, H
• Suzuki, K
• Kim, I
• Spencer, A
• O'Dwyer, M
• Hong, WJ
• Jalaluddin, M
• Yang, XQ
• Pauff, JM
• Maciag, PC
• Ross, JA
• Kumar, S

Abstract

Abstract no disponible